# Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

> **NCT02584959** · PHASE3 · COMPLETED · sponsor: **Shire** · enrollment: 75 (actual)

## Conditions studied

- Hereditary Angioedema (HAE)

## Interventions

- **DRUG:** C1 esterase inhibitor [human] liquid
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02584959
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-01
- **Primary completion:** 2017-07-24
- **Final completion:** 2017-07-24
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2021-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02584959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02584959, "Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02584959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*